The newly enhanced drug development platform will help empower innovators with the fastest development timelines
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
Nearly 1 million people are living with multiple sclerosis in the United States. Spasticity is a commonly reported symptom for MS, with an estimated prevalence of spasticity of 67%
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
It will enable the company to branch out to new geographies and strengthen its presence in South Africa
ICICI Direct’s analysis of Cipla’s Q3FY22 results
In the April-September 2021 period, the FDI inflows continued to be buoyant at Rs 4,413 crore, growing at the rate of 53 per cent over the same period in 2020-21
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
Biocon has reported consolidated financial results for the period ended December 31, 2021
Subscribe To Our Newsletter & Stay Updated
